Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing. It also develops drugs in Phase III clinical trial, including OT-101 for myopia, OT-802 for presbyopia, OT-211 for dry eye disease, and OT-301 for glaucoma; and drugs in Phase I/II clinical trial, such as OT-703 for diabetic macular edema, OT-202 for dry eye disease, and OT-601-C for the treatment of ocular inflammation. In addition, the company engages in the development of drugs in preclinical stage comprising OT-701 for wet age-related macular degeneration, OT-1601 for retinitis pigmentosa and dry age-related macular degeneration, OT-1602 for optic neuritis, and OT-503 for dry eye disease. Further, it is involved in trading of pharmaceutical products; and plant construction. The company was founded in 2017 and is based in Suzhou, China.